conf call pres / q&a

Did anyone join this ?

I did but got dropped off a couple of time and missed the end during the questions.

I thought the presentation was good though as one person raised during q&a it's all very scientific and his concern that the layman will not understand some of the fundamental messages.

This guy posed a good question I thought which was that it looked like there was not a clear comparison between survival of those at the various stages of illness who are not taking Omacetaxine compared to those who are.

In response, ChemGenex passed the opportunity to answer around a bit (I 'm sure it wasn't dodged, I think they were just trying to ensure the right person answered)...then I got dropped off. I did however get the feeling that Prof Collier seemed to try and refocus the discussion on the endpoints rather than encourage that this question got answered. Hard to say.

I recall hearing that for those who are NOT taking Omacetaxine, median survival was as follows:

Advanced: 20 months
Chronic: 12 months
Blast: 2 months

I didn't get to hear how that compared to the same stage patients using Omacetaxine.

Could anyone clarify what got said ?

By the way, from what I did understand, this truly seems like a remarkable drugs that we have a huge impact for Leukemia sufferers.